Trial Profile
An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms ENABLE-ALL
- Sponsors GlaxoSmithKline; GSK
- 15 Oct 2014 New trial record